首页> 外文期刊>Quarterly Journal of Medicine >A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.
【24h】

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.

机译:使用口服糖皮质激素评估患者长期骨折风险的简单评分。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Previous analyses of risk factors for glucocorticoid (GC)-induced osteoporosis have focused on the estimation of relative rather than absolute fracture probability. AIM: To estimate risk scores for the individual probability of fracture in GC users. DESIGN: Retrospective data analysis. METHODS: We evaluated all patients aged 40 years or older with a prescription for oral GCs in the General Practice Research Database (GPRD), which comprises the computerized medical records of around 7 million UK subjects. Individual risk factors for osteoporotic fractures were identified, and combined in a predictive model for 10-year absolute fracture risk. RESULTS: Of 191 752 oral GC users aged > or =40 years, 7412 experienced an osteoporotic fracture. Several characteristics independently contributed to the fracture risk score (GC therapy, age, gender, fall history, fracture history, body mass index, smoking, previous diagnoses, use of medication, recent hospitalization and indication for GC treatment). Scores of 30, 40 and 50 corresponded to absolute 5-year fracture risks of 6.2%, 15.3% and 35.2%, respectively. A woman aged 65 years with RA, low BMI, and a previous history of fracture and falls, who used 15 mg GC daily (total risk score 54) would have a 5-year fracture risk of 47% (a man with similar history, 30.1%). Short-term use of high-dose GC therapy (> or =30 mg) was associated with only a small increased risk of osteoporotic fracture (RR 1.21, 95%CI 1.04-1.42) in patients with a history of GC use. DISCUSSION: This risk score helps to predict an individual's risk of fracture during GC use. Decisions about bone protection treatment could be based on long-term risks of fracture.
机译:背景:先前对糖皮质激素(GC)引起的骨质疏松症的危险因素的分析集中在相对破裂而非绝对破裂几率的估计上。目的:评估GC使用者个人骨折可能性的风险评分。设计:回顾性数据分析。方法:我们在全科医学研究数据库(GPRD)中评估了所有40岁或40岁以上口服GC处方的患者,该数据库包含约700万英国受试者的计算机病历。确定了骨质疏松性骨折的个体危险因素,并将其组合为10年绝对骨折风险的预测模型。结果:在年龄大于或等于40岁的191 752个口服GC用户中,有7412人经历了骨质疏松性骨折。骨折风险评分有几个独立的特征(GC治疗,年龄,性别,跌倒史,骨折史,体重指数,吸烟,既往诊断,药物使用,近期住院和GC治疗适应症)。 30、40和50分分别对应5年绝对骨折风险,分别为6.2%,15.3%和35.2%。如果某位年龄65岁,患有RA,BMI低且有骨折和跌倒史的女性每天使用15 mg GC(总危险评分为54),则5年骨折风险为47%(具有类似病史的男性, 30.1%)。短时间使用大剂量GC治疗(>或= 30 mg)与具有GC使用史的患者发生骨质疏松性骨折的风险增加很小(RR 1.21,95%CI 1.04-1.42)。讨论:该风险评分有助于预测个人在使用GC期间发生骨折的风险。关于骨保护治疗的决定可以基于骨折的长期风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号